Lupin gets USFDA nod to market its postherpetic neuralgia drug

Lupin’s Gabapentin pills get USFDA approval

Drug firm Lupin said it had received approval from the U.S. health regulator to market its generic Gabapentin tablets used for treatment of postherpetic neuralgia in the U.S. The firm has received the final approval to market its Gabapentin tablets USP in the strengths of 600 mg and 800 mg from the USFDA, Lupin said. The company’s tablets are generic version of Pfizer Inc.’s Neurontin tablets in the same strengths.PTI

Recommended for you